Advertisement
Canada markets closed

  • S&P/TSX

    21,656.05
    +13.18 (+0.06%)
     

  • S&P 500

    5,022.21
    -29.20 (-0.58%)
     

  • DOW

    37,753.31
    -45.66 (-0.12%)
     

  • CAD/USD

    0.7260
    -0.0004 (-0.05%)
     

  • CRUDE OIL

    82.85
    +0.16 (+0.19%)
     

  • Bitcoin CAD

    84,166.27
    -3,697.95 (-4.21%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • GOLD FUTURES

    2,382.70
    -5.70 (-0.24%)
     

  • RUSSELL 2000

    1,947.95
    -19.53 (-0.99%)
     

  • 10-Yr Bond

    4.5850
    -0.0740 (-1.59%)
     

  • NASDAQ futures

    17,686.75
    +28.25 (+0.16%)
     

  • VOLATILITY

    18.21
    -0.19 (-1.03%)
     

  • FTSE

    7,847.99
    +27.63 (+0.35%)
     

  • NIKKEI 225

    37,718.15
    -243.65 (-0.64%)
     

  • CAD/EUR

    0.6805
    +0.0003 (+0.04%)
     

Aptose to Present at Canaccord Genuity 2021 Horizons in Oncology Virtual Conference

Aptose Biosciences, Inc.
·2 min read

SAN DIEGO and TORONTO, April 08, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will participate in Canaccord Genuity’s 2021 Horizons in Oncology Virtual Conference:

Canaccord Genuity’s 2021 Horizons in Oncology Virtual Conference

  • Panel: Opportunities in BPDCN and AML

Date:

Thursday, April 15, 2021

Time:

3:00 – 3:55 PM EDT

Format:

Panel Moderated by John Newman, Ph.D., Managing Director, Biotechnology Analyst

Conference Information: Link

The Aptose management team also will be hosting 1x1 meetings during the event.

ADVERTISEMENT

About Aptose

Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage investigational products for hematologic malignancies: luxeptinib (CG-806), an oral, first-in-class mutation-agnostic FLT3/BTK kinase inhibitor, is in a Phase 1a/b trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and non-Hodgkin lymphoma (NHL), who have failed or are intolerant to standard therapies, and is in a separate Phase 1a/b trial in patients with relapsed or refractory acute myeloid leukemia (AML); APTO-253, the only clinical-stage agent that directly targets the MYC oncogene and suppresses its expression, is in a Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory AML or high risk myelodysplastic syndrome (MDS).

For further information, please contact:

Aptose Biosciences Inc.
Susan Pietropaolo
Investor Relations
201-923-2049
spietropaolo@aptose.com

LifeSci Advisors, LLC
Dan Ferry, Managing Director
617-535-7746
Daniel@LifeSciAdvisors.com